Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07246629 · ClinicalTrials.gov registry record · Phase 4
Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Phase 4
- Development phase
- 214
- Enrollment target
NCT07246629 is a Phase 4 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 214 participants.
The verdict
NCT07246629, a Phase 4 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 214 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms.
Interventions
- DRUG Normal Saline
- DRUG Nicardipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07246629
The ClinicalTrials.gov registry entry for NCT07246629 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT07246629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07246629 about?
NCT07246629 is a clinical study titled "Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage". The purpose of this study is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms.
What is the current status of trial NCT07246629?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 214 participants. The study started on 2026-06. Estimated completion is 2027-01.
What interventions are being tested in trial NCT07246629?
The interventions under investigation include: Normal Saline (DRUG), Nicardipine (DRUG).
Who is sponsoring clinical trial NCT07246629?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.